Regulatory tracker: GSK's Blenrep gets all-clear in NICE final guidance
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
By FiercePharma
· Apr 17, 2026
· via FiercePharma
Image: FiercePharma
Tags
policyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
PolicyFierceBiotech ↗
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
PolicyBriefing
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…